2010
DOI: 10.1016/j.yjmcc.2010.04.003
|View full text |Cite
|
Sign up to set email alerts
|

Corrigendum to “Effects of homocysteine on number and activity of endothelial progenitor cells from peripheral blood” [J. Mol. Cell. Cardiol. 36 (2004) 233–239]

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

2011
2011
2014
2014

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(3 citation statements)
references
References 0 publications
0
3
0
Order By: Relevance
“…EPCs were prepared as described previously. 5) Briefly, mononuclear cells were isolated from peripheral blood by Ficoll density gradient centrifugation and cultured on human FN-coated dishes in EGM-2 endothelial medium supplemented with EGM-2-MV-SingleQuots and 20% FBS.…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…EPCs were prepared as described previously. 5) Briefly, mononuclear cells were isolated from peripheral blood by Ficoll density gradient centrifugation and cultured on human FN-coated dishes in EGM-2 endothelial medium supplemented with EGM-2-MV-SingleQuots and 20% FBS.…”
Section: Methodsmentioning
confidence: 99%
“…4) In vitro, homocysteine (Hcy) dose-and time-dependently decreases EPC numbers and impairs cell proliferation, migration, and vasculogenesis capacity. 5) Impaired EPC numbers and functional capacity have been identified in a murine model with HHcy. 6) One possible explanation for the reduced capacity of EPCs is increased apoptosis of premature progenitor cells.…”
Section: Homocysteine-induced Caspase-3 Activation By Endoplasmic Retmentioning
confidence: 99%
“…8 Another proatherosclerotic factor, homocysteine, reduces EPC outgrowth in vitro by accelerating the onset of EPC senescence and thereby inhibiting proliferation. 79,80 Hyperhomocysteinemia is commonly observed in several autoimmune diseases. 81 In RA patients, the release of TNF might be pivotal in reducing EPC levels, as corticosteroid treatment normalized EPC levels 44 and infliximab effectively increased levels of these cells.…”
Section: Epc Levels In the Bone Marrowmentioning
confidence: 99%